Meng Welliver, M.D., Ph.D.

  1. Radiation Oncologist
  1. Garayua-Cruz L, Broida SE, Okuno SH, Robinson SI, Siontis BL, Welliver MX, Wilke BK, Goulding KA, Rose PS, Houdek MT. Outcomes of non-angiosarcoma radiation-associated soft tissue sarcomas of the chest. J Surg Oncol. 2024 Jul; 130 (1):56-63 Epub 2024 June 12
    View PubMed
  2. Wong A, Riley M, Zhao S, Zimmer J, Viveiros M, Wang JG, Esguerra V, Li M, Lopez G, Kendra K, Carbone DP, He K, Alahmadi A, Kaufman J, Memmott RM, Shields PG, Brownstein J, Haglund K, Welliver M, Otterson GA, Presley CJ, Wei L, Owen DH, Ho K. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer. J Natl Compr Canc Netw. 2023 Nov; 21 (11):1164-1171.e5
    View PubMed
  3. Shaker N, Amadi CC, Welliver M, Otterson GA, Liebner DA, Shilo K. A Case of Mediastinal Carcinosarcoma With Beta-HCG Production and KRAS Mutation. Int J Surg Pathol. 2023 Apr 3; 10668969231166297 Epub 2023 Apr 03
    View PubMed
  4. Zeh RD, Konieczkowski D, Shen C, Tsilimigras DI, Kim A, Grignol VP, Contreras CM, Welliver M, Tsung A, Pawlik TM, Pollock RE, Beane JD. Prognostic factors in patients receiving surgery and radiation therapy for retroperitoneal sarcoma: A machine-learning analysis. Surgery. 2023 Mar; 173 (3):640-644 Epub 2022 Nov 08
    View PubMed
  5. Kagan AB, Anders NM, Hemingway A, Lee EQ, Kelly KR, Lee HC, Xu-Welliver M, Piekarz R, Rudek MA. Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2022 Nov; 36 (11):e5467 Epub 2022 Aug 31
    View PubMed
  6. Palmer JD, Prasad RN, Fabian D, Wei L, Yildiz VO, Tan Y, Grecula J, Welliver M, Williams T, Elder JB, Raval R, Blakaj D, Haglund K, Bazan J, Kendra K, Arnett A, Beyer S, Liebner D, Giglio P, Puduvalli V, Chakravarti A, Wuthrick E. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiother Oncol. 2022 May; 170:21-26 Epub 2022 Mar 31
    View PubMed
  7. Yadav M, Liu J, Song F, Mo X, Jacob NR, Xu-Welliver M, Chakravarti A, Jacob NK. Utility of Circulating MicroRNA-150 for Rapid Evaluation of Bone Marrow Depletion After Radiation and Efficiency of Bone Marrow Reconstitution. Int J Radiat Oncol Biol Phys. 2022 Mar 15; 112(4):964-974. Epub 2021 Nov 09.
    View PubMed
  8. Yue D, Liu W, Chen C, Zhang T, Ma Y, Cui L, Gu Y, Bei T, Zhao X, Zhang B, Bai Y, Romero A, Xu-Welliver M, Wang C, Zhang Z, Zhang B. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients. Transl Lung Cancer Res. 2022 Feb; 11(2):263-276.
    View PubMed
  9. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun. 2022 Jan 07; 30:100514. [Epub ahead of print]
    View PubMed
  10. Cai S, Li N, Bai X, Liu L, Banerjee A, Lavudi K, Zhang X, Zhao J, Venere M, Duan W, Zhang J, Welliver MX, He K, Wang QE. ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition. Theranostics. 2022; 12 (16):7051-7066 Epub 2022 Oct 03
    View PubMed
  11. Braggio DA, Costas C de Faria F, Koller D, Jin F, Zewdu A, Lopez G, Batte K, Casadei L, Welliver M, Horrigan SK, Han R, Larson JL, Strohecker AM, Pollock RE. Preclinical efficacy of the Wnt/beta-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors. PLoS One. 2022; 17 (10):e0276047 Epub 2022 Oct 14
    View PubMed
  12. Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V. Corrigendum to: The role of p53 in base excision repair following genotoxic stress. Carcinogenesis. 2021 Jun 21; 42(6):903.
    View PubMed
  13. Xu L, Yang P, Hu K, Wu Y, Xu-Welliver M, Wan Y, Luo C, Wang J, Wang J, Qin J, Rong Y, Niu T. Prediction of neoadjuvant chemotherapy response in high-grade osteosarcoma: added value of non-tumorous bone radiomics using CT images. Quant Imaging Med Surg. 2021 Apr; 11(4):1184-1195.
    View PubMed
  14. Li Y, Dong R, Lu M, Cheng C, Feng Z, Zhao R, Liang J, Han J, Jiang J, Xu-Welliver M, Renaud S, Tian H. Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma. Transl Lung Cancer Res. 2021 Apr; 10(4):1841-1856.
    View PubMed
  15. Sebastian NT, Merritt RE, Abdel-Rasoul M, Wu T, Bazan JG, Xu-Welliver M, Haglund K, D'Souza D, Kneuertz PJ, Williams TM. Recurrence After Stereotactic Body Radiation Therapy Versus Lobectomy for Non-Small Cell Lung Cancer. Ann Thorac Surg. 2020 Sep; 110 (3):998-1005 Epub 2020 Apr 27
    View PubMed
  16. Yadav M, Bhayana S, Liu J, Lu L, Huang J, Ma Y, Qamri Z, Mo X, Jacob DS, Parasa ST, Bhuiya N, Fadda P, Xu-Welliver M, Chakravarti A, Jacob NK. Two-miRNA-based finger-stick assay for estimation of absorbed ionizing radiation dose. Sci Transl Med. 2020 Jul 15; 12 (552)
    View PubMed
  17. Sebastian NT, Raj R, Prasad R, Barney C, Brownstein J, Grecula J, Haglund K, Xu-Welliver M, Williams TM, Bazan JG. Association of Pre- and Posttreatment Neutrophil-Lymphocyte Ratio With Recurrence and Mortality in Locally Advanced Non-Small Cell Lung Cancer. Front Oncol. 2020; 10:598873 Epub 2020 Nov 05
    View PubMed
  18. Sebastian N, Wu T, Driscoll E, Willers H, Kelly S, Musunuru HB, Mo X, Tan Y, Bazan J, Haglund K, Xu-Welliver M, Baschnagel AM, Ju A, Keane F, Williams TM. Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer. Radiother Oncol. 2019 Nov; 140:26-33 Epub 2019 June 05
    View PubMed
  19. Sebastian N, Wu T, Bazan J, Driscoll E, Willers H, Yegya-Raman N, Bond L, Dwivedi A, Mo X, Tan Y, Xu-Welliver M, Haglund K, Jabbour SK, Keane FK, Williams TM. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2019 May; 134:151-157 Epub 2019 Feb 15
    View PubMed
  20. Pollock RE, Payne JE, Rogers AD, Smith SM, Iwenofu OH, Valerio IL, Zomerlei TA, Howard JH, Dornbos D 3rd, Galgano MA, Goulart C, Mendel E, Miller ED, Xu-Welliver M, Martin DD, Haglund KE, Bupathi M, Chen JL, Yeager ND. Multidisciplinary sarcoma care. Curr Probl Surg. 2018 Dec; 55 (12):517-580 Epub 2018 Nov 09
    View PubMed
  21. Miller ED, Fisher JL, Haglund KE, Grecula JC, Xu-Welliver M, Bertino EM, He K, Shields PG, Carbone DP, Williams TM, Otterson GA, Bazan JG. Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiat Oncol. 2018 Oct 5; 13 (1):196 Epub 2018 Oct 05
    View PubMed
  22. Sebastian NT, Xu-Welliver M, Williams TM. Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances. J Thorac Dis. 2018 Aug; 10 (Suppl 21):S2451-S2464
    View PubMed
  23. Barney CL, Scoville N, Allan E, Ayan A, DiCostanzo D, Haglund KE, Grecula J, Williams T, Xu-Welliver M, Otterson GA, Bazan JG. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. Int J Radiat Oncol Biol Phys. 2018 Mar 1; 100 (3):748-755 Epub 2017 Nov 23
    View PubMed
  24. Miller ED, Fisher JL, Haglund KE, Grecula JC, Xu-Welliver M, Bertino EM, He K, Shields PG, Carbone DP, Williams TM, Otterson GA, Bazan JG. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Mar; 13 (3):426-435 Epub 2018 Jan 08
    View PubMed
  25. Xu-Welliver M, Carbone DP. Blood-based biomarkers in lung cancer: prognosis and treatment decisions. Transl Lung Cancer Res. 2017 Dec; 6 (6):708-712
    View PubMed
  26. Bhayana S, Song F, Jacob J, Fadda P, Denko NC, Xu-Welliver M, Chakravarti A, Jacob NK. Urinary miRNAs as Biomarkers for Noninvasive Evaluation of Radiation-Induced Renal Tubular Injury. Radiat Res. 2017 Dec; 188 (6):626-635 Epub 2017 Oct 04
    View PubMed
  27. Wald P, Mo X, Barney C, Gunderson D, Haglund AK, Bazan J, Grecula J, Chakravarti A, Williams T, Carbone DP, Xu-Welliver M. Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Dec; 12 (12):1779-1787 Epub 2017 Aug 24
    View PubMed
  28. Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA, Rochford R, Porcu P. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. Curr Hematol Malig Rep. 2016 Dec; 11 (6):514-527
    View PubMed
  29. Miller ED, Mo X, Andonian NT, Haglund KE, Martin DD, Liebner DA, Chen JL, Iwenofu OH, Chakravarti A, Scharschmidt TJ, Mayerson JL, Pollock RE, Xu-Welliver M. Patterns of major wound complications following multidisciplinary therapy for lower extremity soft tissue sarcoma. J Surg Oncol. 2016 Sep; 114(3):385-91. Epub 2016 May 30.
    View PubMed
  30. Salamekh S, Rong Y, Ayan AS, Mo X, Williams TM, Mayr NA, Grecula JC, Chakravarti A, Xu-Welliver M. Inter-Fraction Tumor Volume Response during Lung Stereotactic Body Radiation Therapy Correlated to Patient Variables. PLoS One. 2016; 11(4):e0153245. Epub 2016 Apr 06.
    View PubMed
  31. Haverkos B, Tyler K, Gru AA, Winardi FK, Frederickson J, Hastings J, Elkins C, Zhang X, Xu-Welliver M, Wong HK, Porcu P. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University. Oncologist. 2015 Oct; 20 (10):1161-6 Epub 2015 Aug 25
    View PubMed
  32. Miller ED, Xu-Welliver M, Haglund KE. The role of modern radiation therapy in the management of extremity sarcomas. J Surg Oncol. 2015 Apr; 111(5):599-603. Epub 2014 Nov 03.
    View PubMed
  33. Li G, Xie B, Li X, Chen Y, Xu Y, Xu-Welliver M, Zou L. Downregulation of peroxiredoxin-1 by beta-elemene enhances the radiosensitivity of lung adenocarcinoma xenografts. Oncol Rep. 2015 Mar; 33 (3):1427-33 Epub 2015 Jan 19
    View PubMed
  34. Rong Y, Bazan JG, Sekhon A, Haglund K, Xu-Welliver M, Williams T. Minimal Inter-Fractional Fiducial Migration during Image-Guided Lung Stereotactic Body Radiotherapy Using SuperLock Nitinol Coil Fiducial Markers. PLoS One. 2015; 10(7):e0131945. Epub 2015 Jul 09.
    View PubMed
  35. Majithia L, Rong Y, Siddiqui F, Hattie T, Gupta N, Weldon M, Chakravarti A, Wong HK, Porcu P, Xu-Welliver M. Treating cutaneous T-cell lymphoma with highly irregular surfaces with photon irradiation using rice as tissue compensator. Front Oncol. 2015; 5:49. Epub 2015 Feb 24.
    View PubMed
  36. Rong Y, Evans J, Xu-Welliver M, Pickett C, Jia G, Chen Q, Zuo L. Dosimetric evaluation of intensity-modulated radiotherapy, volumetric modulated arc therapy, and helical tomotherapy for hippocampal-avoidance whole brain radiotherapy. PLoS One. 2015; 10(4):e0126222. Epub 2015 Apr 20.
    View PubMed
  37. Tyler KH, Haverkos BM, Hastings J, Hu E, Philips R, Gru AA, Welliver MX, Mishra A, Wong HK, Porcu P. The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma. Front Oncol. 2015; 5:136 Epub 2015 June 17
    View PubMed
  38. Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst. 2014 Nov; 106 (11) Epub 2014 Oct 18
    View PubMed
  39. Xu-Welliver M, Yuh WT, Fielding JR, Macura KJ, Huang Z, Ayan AS, Backes FJ, Jia G, Moshiri M, Zhang J, Mayr NA. Imaging across the life span: innovations in imaging and therapy for gynecologic cancer. Radiographics. 2014 Jul-Aug; 34 (4):1062-81
    View PubMed
  40. Liebner DA, Walston SA, Cavaliere R, Powers CJ, Sauvageau E, Lehman NL, Wayne Slone H, Xu-Welliver M, Xia F, Kendra KL. Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res. 2014 Apr; 24 (2):172-6
    View PubMed
  41. Rong Y, Walston S, Welliver MX, Chakravarti A, Quick AM. Improving intra-fractional target position accuracy using a 3D surface surrogate for left breast irradiation using the respiratory-gated deep-inspiration breath-hold technique. PLoS One. 2014; 9(5):e97933. Epub 2014 May 22.
    View PubMed
  42. Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W, Otterson GA. Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagn Pathol. 2013 Dec 10; 8:201.
    View PubMed
  43. Lin SH, George TJ, Ben-Josef E, Bradley J, Choe KS, Edelman MJ, Guha C, Krishnan S, Lawrence TS, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman CN, Vikram B, Yoo S, Chung CH, Participants on Workshop for Preclinical and Clinical Development of Radiosensitizers, National Cancer Institute. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst. 2013 May 15; 105(10):686-93. Epub 2013 Mar 15.
    View PubMed
  44. Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M, Kong M. The B55a subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol Cell. 2013 Apr 25; 50(2):200-11. Epub 2013 Mar 14.
    View PubMed
  45. Xu-Welliver M, Lin LL. Evaluation of a balloon-based vaginal packing system and patient-controlled analgesia for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):263-8. Epub 2012 Dec 08.
    View PubMed
  46. Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. J Gastrointest Cancer. 2012 Dec; 43(4):612-8.
    View PubMed
  47. Li G, Xie B, Li X, Chen Y, Wang Q, Xu Y, Xu-Welliver M, Zou L. Down-regulation of survivin and hypoxia-inducible factor-1 a by ß-elemene enhances the radiosensitivity of lung adenocarcinoma xenograft. Cancer Biother Radiopharm. 2012 Feb; 27(1):56-64. Epub 2012 Jan 16.
    View PubMed
  48. Shen J, Metz JM, Zhu TC, Panetta J, Finlay JC, Xu-Welliver M, Plastaras JP, Bar Ad V, Both S. Dosimetric consequences of pancreatic tumor motion when predetermined treatment margins are employed during intensity-modulated radiation therapy. J BUON. 2012 Jul-Sep; 17(3):526-32.
    View PubMed
  49. Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V. The role of p53 in base excision repair following genotoxic stress. Carcinogenesis. 2004 Jan; 25(1):11-9. Epub 2003 Oct 10.
    View PubMed
  50. Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, Harris CC. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest. 2003 Dec; 112 (12):1887-94
    View PubMed
  51. Liu L, Xu-Welliver M, Kanugula S, Pegg AE. Inactivation and degradation of O(6)-alkylguanine-DNA alkyltransferase after reaction with nitric oxide. Cancer Res. 2002 Jun 01; 62(11):3037-43.
    View PubMed
  52. Xu-Welliver M, Pegg AE. Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase. Carcinogenesis. 2002 May; 23(5):823-30.
    View PubMed
  53. Cai Y, Wu MH, Xu-Welliver M, Pegg AE, Ludeman SM, Dolan ME. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res. 2000 Oct 01; 60(19):5464-9.
    View PubMed
  54. Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S, Seshadri R, Pegg AE, Williams DA. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 2000 Sep 15; 60(18):5187-95.
    View PubMed
  55. Liu H, Xu-Welliver M, Pegg AE. The role of human O(6)-alkylguanine-DNA alkyltransferase in promoting 1,2-dibromoethane-induced genotoxicity in Escherichia coli. Mutat Res. 2000 Jul 20; 452(1):1-10.
    View PubMed
  56. Xu-Welliver M, Kanugula S, Loktionova NA, Crone TM, Pegg AE. Conserved residue lysine165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine. Biochem J. 2000 Apr 15; 347 (Pt 2):527-34
    View PubMed
  57. Xu-Welliver M, Pegg AE. Point mutations at multiple sites including highly conserved amino acids maintain activity, but render O6-alkylguanine-DNA alkyltransferase insensitive to O6-benzylguanine. Biochem J. 2000 Apr 15; 347 (Pt 2):519-26
    View PubMed
  58. Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum Gene Ther. 1999 Nov 20; 10(17):2769-78.
    View PubMed
  59. Xu-Welliver M, Leitão J, Kanugula S, Meehan WJ, Pegg AE. Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine. Biochem Pharmacol. 1999 Oct 15; 58(8):1279-85.
    View PubMed
  60. Loktionova NA, Xu-Welliver M, Crone TM, Kanugula S, Pegg AE. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine. Biochem Pharmacol. 1999 Jul 15; 58(2):237-44.
    View PubMed
  61. Xu-Welliver M, Leitão J, Kanugula S, Pegg AE. Alteration of the conserved residue tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine. Cancer Res. 1999 Apr 01; 59(7):1514-9.
    View PubMed
  62. Xu-Welliver M, Kanugula S, Pegg AE. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. Cancer Res. 1998 May 01; 58(9):1936-45.
    View PubMed